- Home
- FLYE vs CMND Comparison
FLYE vs CMND Comparison
Compare FLYE & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLYE | CMND |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 2.6M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FLYE | CMND |
|---|---|---|
| Price | $2.10 | $6.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.2M | 146.9K |
| Earning Date | 09-01-2026 | 09-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.82 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,063,357.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.22 | $0.07 |
| 52 Week High | $109.00 | $7.16 |
Technical Indicators
Market Signals| Indicator | FLYE | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 62.21 | 90.06 |
| Support Level | $1.53 | $0.65 |
| Resistance Level | $2.29 | N/A |
| Average True Range (ATR) | 0.27 | 0.35 |
| MACD | 0.11 | 0.67 |
| Stochastic Oscillator | 40.44 | 91.56 |
Price Performance
Historical ComparisonAbout FLYE Fly-E Group Inc.
Fly-E Group Inc is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters, and related accessories under the Fly E-Bike brand. It offers 27 E-motorcycle products, 37 E-bike products and 38 E-scooter products.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.